

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/86, 5/10, 7/01, C07K 14/47	A2	(11) International Publication Number: WO 99/13073 (43) International Publication Date: 18 March 1999 (18.03.99)
(21) International Application Number: PCT/JP98/04010 (22) International Filing Date: 7 September 1998 (07.09.98) (30) Priority Data: 9/259235 8 September 1997 (08.09.97) JP (71) Applicant (for all designated States except US): RPR GENCELL ASIA/PACIFIC INC. [JP/JP]; 20-3, Hinode 2-chome, Funabashi-shi, Chiba 273-0015 (JP). (72) Inventor; and (75) Inventor/Applicant (for US only): HAMADA, Hirofumi [JP/JP]; 2-3-1-310, Kaga, Itabashi-ku, Tokyo 173-0003 (JP). (74) Agents: ODAJIMA, Heikichi et al.; Odajima Patent Office, Nippon Jitensha Building, 9-15, Akasaka 1-chome, Mi- nato-ku, Tokyo 107-0052 (JP).		(81) Designated States: AU, CA, KR, NZ, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: VIRAL VECTOR SYSTEM CAPABLE OF EXPRESSING AN APOPTOSIS-ASSOCIATED GENE (57) Abstract An apoptosis-resistant virus-sensitive cell is disclosed. This cell has an apoptosis resistance gene, such as crmA, bcl-2, bcl-x1, FLIP, survivin, IAP, or ILP gene. The generation of adenovirus vectors capable of expressing apoptosis-associated genes is achieved using said cell.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

VIRAL VECTOR SYSTEM CAPABLE OF EXPRESSING AN
APOPTOSIS-ASSOCIATED GENE

5

Technical Field

This invention relates to viral vector systems capable of expressing apoptosis-associated genes. More particularly, it relates to recombinant viruses contain-
10 ing apoptosis-associated genes, and systems for generating such viruses.

Background Art

In addition to congenital diseases, a great
15 variety of acquired diseases have become the object of gene therapy. In order to transfer objective genes, vectors designed variously according to the target cell and the objective gene have been proposed. It may
safely be said that these designs are being made princi-
20 pally from the viewpoint of gene transfer efficiency and safety.

However, for some objective genes to be transferred, recombinant viruses cannot always be generated efficiently or cannot possibly be generated. More
25 specifically, in generating a recombinant virus by the infection of a certain virus-sensitive cell with a virus or the transfection thereof with an expression plasmid, it will be very difficult to obtain the desired recombinant virus if the expression of the objective gene
30 integrated into the virus causes cell damage (in particular, apoptosis) to the aforesaid cell.

Actually, in order to generate a recombinant adenovirus containing an apoptosis-associated gene as the objective gene, the present inventors carried out a
35 conventional method using the ordinary 293 cell line, but failed to obtain a recombinant adenovirus capable of

expressing the FAS (CD 95), Fas Lig, Bcl-2, Bcl-2 anti-sense or Bax gene. The reason for this seems to be that, if an adenovirus vector capable of expressing an apoptosis-associated gene is introduced into animal
5 cells, the cells producing the virus will be destroyed because the period of time required to induce cell death by apoptosis is shorter than that required to replicate and produce the virus, resulting in failure to obtain a recombinant virus having an apoptosis-associated gene
10 integrated thereinto.

There are a variety of diseases for which the induction of apoptosis by gene transfer or, on the contrary, the inhibition of harmful apoptosis by gene transfer serves as an effective therapeutic means.
15 Accordingly, a need for a means which enables recombinant viruses capable of expressing apoptosis-associated genes to be generated efficiently will continue to exist.

20 Disclosure of Invention

The present inventors have now found that the above-described problem (i.e., the inability of the conventional method to generate a recombinant virus capable of an apoptosis-associated gene) can be solved
25 by establishing an apoptosis-resistant 293 cell line. In addition to the 293 cell line, the establishment of such cell lines can likewise be applied to other cell lines usable as producer cells, owing to their mechanism of action.

30 Thus, the present invention provides an apoptosis-resistant virus-sensitive cell line having an apoptosis resistance gene introduced thereinto. By using this cell line as a producer cell, a virus having an apoptosis-associated gene integrated thereinto in an
35 expressible form can be generated efficiently.

Accordingly, the present invention also provides

a method for the generation of a recombinant virus containing an apoptosis-associated gene, and such recombinant viruses. By properly choosing the genes contained therein, such recombinant viruses are useful as
5 vectors for gene therapy which can be applied to cancer therapy for destroying cancer cells selectively, the treatment of autoimmune diseases and graft rejection reactions, and apoptosis induction therapy for inflammatory cells in inflammatory diseases.

10

Brief Description of Drawings

Fig. 1 is a photograph substituting for a figure to show that 293/crmA cells are resistant to transfection with pAxCAhFasLig plamid DNA. This photograph
15 exhibits microscopic observation (magnification: 100) of the state of cells on the day after the transfection. 293 cells of parent strain suffered serious damage from the transfection (See: photograph A). In contrast, 293/crmA cells received almost no damage (See: photograph B). Transfection was conducted in the following
20 manner: 293 cells and 293/crmA cells were inoculated each 40,000 in number in a 6 cm dish, and, two days later, were each transfected with 0.016 mg of pAxCAhFasLig plamid DNA by means of calcium phosphate
25 method.

Fig. 2 is a graph to show that strong expression of FAS is caused by the infection with recombinant adenovirus AxCAhFAS. As a control, U251 cells were infected with AxCALacZ at an moi of 100. Anti-human CD
30 95-FITC (Pharmingen) was used as a primary antibody in an amount of 10 μ l per 1×10^6 cells, and anti-Leu 2a (anti-CD 8)-FITC (Becton Dickinson Immunocytometry Systems, San Jose, CA) was used as a control antibody in an amount of 10 μ l per 1×10^6 cells. It was confirmed
35 that the expression of FAS in U251 cells was very greatly enhanced by infection with the recombinant adenovirus

AxCAhFAS (Peak 4). Peak 1 shows U251 cells stained with the control antibody. Peak 2 shows uninfected U251 cells stained with anti-human CD 95-FITC (Pharmingen). In U251 cells, a slight expression of FAS is observed.

5 Peak 3 shows U251 cells infected with AxCalacZ as a control. Although infection with the simple adenovirus causes a slight change in the expression level of FAS, said change is very little as compared with the change shown by peak 4.

10 Fig. 3 is a graph to show that strong expression of FAS ligand is caused by the infection with recombinant adenovirus AxCAhFasLig. It was confirmed that the expression of FAS ligand in U373 cells was induced by infection with the FAS ligand adenovirus (AxCAhFasLig).

15 Peak 1 shows the results of analysis of control U373 cells, and peak 2 shows the results of analysis of U373 cells infected with the FAS ligand adenovirus (AxCAhFasLig).

Fig. 4 is a micrograph (magnification: 100) substituting for a figure to show the state of subline of U251 (U251-FAS-H) two days after infected with AxCAhFADD. When growing, U251 cells inherently keep adhered to a plastic plate. In this micrograph, however, most of the cells are caused to float on the surface by the infection with AxCAhFADD.

Fig. 5 is a photograph substituting for a figure to exhibit the results of western blot analysis (gel filtration electrophoresis) which show that human FADD is strongly expressed on account of the infection with adenovirus AxCAhFADD. Human glioma cells U373 were infected with the adenovirus AxCAhFADD at moi of 100, and, two days after the infection, proteins were extracted from the cells and were then subjected to western blot analysis. Lane 1 shows uninfected control U373 cells. Lane 2 shows control U373 cells infected with AxCA-lacZ at moi of 100. Lane 3 shows the results of

western blot analysis of proteins extracted from U373 cells which had been infected with AxCAhFADD at moi of 100. These analyses were carried out according to an ordinary procedure with use of a commercially available
5 anti-FADD antibody (Santa-Cruz, polyclonal anti-FADD antibody).

Specific Description of the Invention

In the context of the present invention, the
10 term "apoptosis resistance gene" denotes any gene that, when a producer cell is generated by introducing the gene thereinto, can impart thereto resistance to apoptosis due to the expression of an apoptosis-associated gene, without regard to the type thereof. As used
15 herein, the expression "can impart thereto resistance to apoptosis" means the ability to modify the producer cell in such a way that, when a virus containing an apoptosis-associated gene is introduced thereinto, the producer cell can survive for a longer period of time
20 than that required to replicate and produce the gene. Examples of such apoptosis resistance genes include, but are not limited to, the crmA gene [cowpox virus white-pock variant (CPV-W2) (crmA): Pickup, D.J. et al., Proc. Natl. Acad. Sci. U.S.A. 83, 7698- 7702 (1986); J.
25 Virol. 63, 4632-4644 (1989)], the bcl-2 gene [Reed, J.C., J. Cell Biol. 124, 1-6, 1994], the bcl-xl gene [Boise, L.H. et al., Cell 74(4), 597-608 (1993)], the FLIP gene [human FLICE-like inhibitory protein: Irmeler et al., Nature 388, 190-195, 1997], the survivin gene
30 [IAP-like apoptosis inhibitor: Ambrosini et al., Nature Medicine 8, 917-921, 1997], the IAP gene [baculovirus apoptosis-inhibiting protein: Boise et al., J. Virol. 67, 2168-2174, 1993] and the ILP gene [IAP-like protein ILP: Duckett et al., EMBO J. 15(11), 2685- 2694, 1996].

35 The cell from which the producer cell is derived may be any virus-sensitive cell that meets the purpose

of the present invention. However, an especially preferred example thereof is the 293 cell line used for the multiplication of adenoviruses. For example, in the case of infection with an adenovirus, it is preferably
5 to use a properly modified cell line, such as one having introduced therein the E1 gene which is usually the first to be expressed after infection with an adenovirus [Becker, T.C. et al., Methods in Cell Biol. 43, 161-189 (1994)].

10 Moreover, this cell line must be infectible with viruses belonging to a family selected from the group consisting of the families *Adenoviridae*, *Retroviridae*, *Parvoviridae*, *Herpesviridae*, *Poxviridae*, *Papovaviridae* and *Hepadnaviridae*. Preferably, this cell line must
15 have the property of being at least infectible with human adenoviruses belonging to the family *Adenoviridae*.

Specific examples of the above-defined cell line include 293/crmA, 293/bcl-2 and 293/bcl-xl.

According to the present invention, a recombi-
20 nant virus containing (or having integrated therein) an apoptosis-associated gene can be efficiently generated (or produced) by using a cell line (or producer) as described above. This may be accomplished by providing an apoptosis-resistant cell line as described above;
25 infecting or transfecting cells of this cell line with a virus (or expression vector) having an apoptosis-associated gene integrated therein in the presence of a gene unit capable of replicating or producing the virus, a helper virus (serving, for example, to make up for the
30 function of the gene removed to integrate the apoptosis-associated gene) or the like, if necessary; and culturing the infected (or transfected) cells to multiply the recombinant virus. The respective steps of this procedure may be carried out according to the techniques well
35 known to those skilled in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd. ed., 1989,

Cold Spring Harbor Laboratory Press, New York; Saito and Sugano (eds.), "An Extra Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodosha]. In the case of viruses

- 5 belonging to the family *Parvoviridae* (e.g., adeno-associated viruses), a helper virus such as an adenovirus is used in combination with them.

Thus, according to the present invention, a recombinant virus having an apoptosis-associated gene
10 integrated therinto can be obtained in large amounts. The term "apoptosis-associated gene" as used herein comprehends all genes that permit recombinant viruses to be generated in the above-described manner and used as a means of gene therapy for the treatment of diseases in
15 animals including man. Specific examples of such genes include, but are not limited to, the FAS gene [in particular, human FAS; Ito, N. et al., Cell 66, 233- 243 (1991)], the Fas Lig gene [human Fas ligand gene; see Mita et al., Biochem. Biophys. Res. Comm. 204, 468-474],
20 the FLICE gene [human FADD-homologous ICE/CED three-way protease gene; Muzio, M. et al., Cell 85(6), 817-827 (1996)] and the bcl-xs gene [Boise, L.H. et al., Cell 74(4), 597-608 (1993)]. These genes are inserted into a position of viral DNA from which a gene that is ex-
25 pressed in animal cells upon infection with the virus and functions to produce the virus has been removed in advance, according to the per se known techniques [Sato et al., Methods for the Generation of Recombinant Adenoviruses, pp. 27-42; Saito and Sugano (eds.), "An Extra
30 Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodosha]. Specific examples of the virus have been given above. The recombinant virus (or expression vector) so generated may be introduced into cells of the above-
35 described cell line and multiplied therein. Thus, a recombinant virus (or vector) in accordance with the

present invention can be obtained.

As described above, preferred examples of the virus used in the present invention are human adenoviruses which are already being used as vectors for gene therapy. They also include all variants that have been modified in such a way as to meet the purpose of the present invention.

As will be described later in greater detail, recombinant adenoviruses can be generated by using the 293/crmA cell line according to one specific embodiment of the present invention and transfecting it with an adenovirus-derived plasmid pAx CA- [Miyake, S., Maki-mura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. (1996), Proc. Natl. Acad. Sci. USA 93, 1320-1324; and Niwa, H., Yamamura, K., and Miyazaki, J. (1991), Gene (Amst.) 108, 193-200] into which an apoptosis-associated gene as described above has been integrated. Specific examples of such recombinant adenoviruses include AxCA-FAS (CD 95), AxCA-Fas Lig, AxCA-FLICE (Caspase-8) and AxCA-bcl-xs.

These recombinant adenoviruses serve to introduce the objective gene into target cells in vitro, ex vivo or in vivo.

The present invention is more specifically described hereinbelow by using the 293/crmA cell line as the apoptosis-resistant virus-sensitive cell line and Ax CA-FAS (CD 95), Ax CA-Fas Lig or Ax bcl-xs as the virus (or expression vector) containing an apoptosis-associated gene. However, the following examples are not to be construed to limit the scope of the present invention.

Example 1: Generation of an apoptosis-resistant virus-sensitive cell line 293/crmA

Preparation of pRx-crmA-bsr (Kozak) from pCDNA 3 crmA:

a) pCDNA 3 crmA (obtained from Dr. David J. Pickup) was digested with *EcoRI* to excise an about 1468

bp fragment containing *crmA*. This fragment was cloned into the *EcoRI* site of pRx-bsr [for pRx, see Wakimoto et al., Jap. J. Cancer Res. 88, 296-305 (1997); and for the DNA sequence of bsr, see SEQ ID NO:1 that will be given later] to generate pRx-*crmA*-bsr (not Kozak) having *crmA* inserted therein in the right direction.

19]

b) On the other hand, an *XhoI*-*NcoI* fragment (about 2034 bp) was obtained from pRx-nZ (see the aforementioned article by Wakimoto et al.), an *NcoI*-*NotI* fragment (about 1220 bp) from pRx-*crmA*-bsr, and an *NotI*-*XhoI* fragment (about 4537 bp) from pRx-*crmA*-bsr. These fragments were linked together to generate pRx-*crmA*-bsr (Kozak).

In pRx-*crmA*-bsr (Kozak), the base sequence in the neighborhood of the initiation codon of *crmA* was designed so as to consist of the consensus sequence of Kozak. The full-length gene sequence of this pRx-*crmA*-bsr (Kozak) is shown as SEQ ID NO:1. In this sequence, a base sequence consisting of a large number of "A"s arranged on the outside of the LTR of the retrovirus represents an unidentified sequence part for convenience' sake.

Introduction of the *crmA* gene into 293 cells:

A basic method for gene transfer by use of a retrovirus vector is described in Shinoura and Hamada, "Retroviruses", pp. 58-62; and Saito and Sugano (eds.), "An Extra Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodosha. In this example, the method described in the above references was basically employed to establish a cell line capable of expressing *crmA* on a high level. However, the method employed in this example was based on selection with blasticidin.

Twenty hours before transfection, 5.5×10^6 BOSC 23 packaging cells (see Pear, W.S. et al., Proc. Natl.

Acad. Sci. USA 90, 8392-8396, 1993) were inoculated in a 10 cm dish. In this case, 30 ml of a cell suspension having a density of 5.5×10^5 cells per ml was prepared and 8-, 10- and 12-ml portions thereof were inoculated on three plates. On the next day, a plate showing 80% confluency was chosen. In order to achieve a high titer, it is most important that BOSC cells are inoculated so as to be uniformly scattered without forming lumps. To this end, BOSC cells may be inoculated once more on the previous day.

800 μ l of OPTI-MEM (Gibco/BRL) was gently added to 25 μ l of pRx-crmA-bsr, followed by agitation (fluid A). Separately, 750 μ l of OPTI-MEM was placed in a sterilized tube, and 50 μ l of LIPOFECTAMINE (Gibco/BRL) (see Neumann, J.R. et al., Biotechniques 5, 444, 1987) (2 mg/ml) was slowly added thereto and suspended therein (fluid B).

Fluid A was mixed with fluid B, and this mixture (fluid C) was allowed to stand at room temperature for 40 minutes. BOSC 23 cells were washed once with warm Dulbecco modified Eagle's medium (DMEM) free of an antibiotic and fetal bovine serum (FBS), followed by the addition of fluid C to the BOSC 23 cells. Moreover, 2.4 ml of OPTI-MEM was added and the resulting suspension was incubated for 5 hours in the presence of 5% CO₂. Then, DMEM containing 4 ml of 20% FBS was added and the incubation was continued overnight. On the next day, the culture medium was replaced by warm Dulbecco modified Eagle's medium (complete) containing 10% FBS. At the same time, 2×10^6 packaging cells of the Ψ CRIP-P131 cell line (see Dranoff, G. et al., Proc. Natl. Acad. Sci. USA, 90, 3539-3543, 1993; and for the Ψ CRIP-P131 cell line, see Wakimoto, H. et al., Jp. J. Cancer Res. 88, 296-305, 1997) were inoculated in a 10 cm dish.

After 24 hours, the culture medium of the BOSC 23 cells was filtered through a 0.45 or 0.22 μ m syringe

filter, and Polybrene (hexadimethrine bromide, SIGMA H-9263) was added so as to give a final concentration of 8 $\mu\text{g}/\text{ml}$. 5 ml of this culture medium was added to the cells of the $\Psi\text{CRIP-P131}$ cell line and incubated. After 16 hours' incubation, 5 ml of fresh Dulbecco's medium (complete) was added and the incubation was further continued overnight. The resulting ΨCRIP producer cells were cultured for 7 days in Dulbecco's medium (complete) containing 10 $\mu\text{g}/\text{ml}$ of blasticidin (Funakoshi) to establish $\Psi\text{CRIP}/\text{crmA}$.

For purposes of infection, 293 cells were inoculated in a dish on the day before infection. As soon as about 80% confluency was reached, 5 ml of the supernatant obtained by filtering the culture medium of the aforesaid $\Psi\text{CRIP}/\text{crmA}$ producer cells (which had been replaced by a fresh medium before 24 hours) and adding 8 $\mu\text{g}/\text{ml}$ of Polybrene was added thereto.

After 16 hours' incubation, 5 ml of fresh Dulbecco's medium (complete) was added thereto and the incubation was further continued overnight. The resulting 293 cells were cultured for 7 days in Dulbecco's medium (complete) containing 10 $\mu\text{g}/\text{ml}$ of blasticidin (Funakoshi), and then cultured for about 10 days in Dulbecco's medium (complete) containing no blasticidin to establish 293/ crmA . Thus, there was obtained an apoptosis-resistant 293/ crmA cell line. This 293/ crmA cell line is resistant to transfection with plasmid DNA (e.g., pAxCAhFasL) capable of expressing an apoptosis-associated gene, as shown in Fig. 1. On the basis of this property, vectors can be generated as will be described later.

The base sequence of the plasmid pRx-ires-bsr used in this example is shown as SEQ ID NO:2. In this sequence, a base sequence consisting of a large number of "A"s arranged on the outside of the LTR of the retrovirus represents an unidentified sequence part for

convenience' sake. The plasmid pRx-ires used in this example is reported in Wakimoto, H. et al., Jp. J. Cancer Res. 88, 296-305, 1997. The bsr gene used in this example was generously supplied by Prof. Junichi Fujisawa, Department of Microbiology, Kansai Medical College.

Example 2: Generation of an apoptosis-resistant virus-sensitive cell line 293/bcl-xl

a) cDNA clone of Bcl-xl:

10 The base sequence of the cDNA of Bcl-xl is described in Boise, L.H. et al., Cell 74(4), 597-608 (1993).

In this example, pSKIIhBcl-xl generously supplied by Dr. Andy Minn, University of Chicago, Gwen Knapp Center for Lupus and Immunology Research (Fax 773-702-1576) was used for the cDNA of Bcl-xl. Of the reported cDNA base sequence, the nt135-nt836 translational region (about 700 bp) is contained in this plasmid. However, the base sequences of the parts upstream and downstream thereof are unknown because no information about it has been obtained from Dr. Andy Minn.

b) Construction of the plasmid pCA-Bcl-xl:

An *EcoRI* fragment (about 770 bp) containing hBcl-xl was excised from pSKIIhBcl-xl and subcloned into the *EcoRI* site of pCAcc to generate pCA-Bcl-xl. For pCAcc, see Yoshida Y et al., Biochem. biophys. Res. Commun. 230, 426-430 (1997).

c) Construction of pRx-Bcl-xl-bsr:

This *EcoRI* fragment was integrated into the *EcoRI* site of pRx-bsr. Thus, pRx-Bcl-xl-bsr containing the fragment in the right direction was obtained. The base sequence thereof is shown as SEQ ID NO:3.

In this sequence, a base sequence consisting of a large number of "A"s arranged on the outside of the LTR of the retrovirus represents an unidentified sequence part for convenience' sake. Moreover, the base

sequences of the parts upstream and downstream of the cDNA of Bcl-xl are conveniently represented by AAAAAAAAAA (i.e., ten "A"s) because their ranges are unknown.

5 d) Generation of Ψ CRIP-P131/Bcl-xl:

A basic method for gene transfer by use of a retrovirus vector is described in Shinoura and Hamada, "Retroviruses", pp. 58-62; and Saito and Sugano (eds.), "An Extra Issue of Experimental Medicine: Experimental
10 Methods for Gene Transfer and Expression Analysis", 1997, Yodosha. For the Ψ CRIP-P131 cell line, see the aforementioned article by Wakimoto H. et al. Also in this example, the method described in the above references was basically employed to establish a cell line
15 capable of expressing Bcl-xl on a high level. However, the method employed in this example was based on selection with blasticidin.

The transfection of BOSC 23 cells with the plasmid DNA of pRx-Bcl-xl-bsr was performed in the same
20 manner as previously described for pRx-crmA-bsr. The method for infecting Ψ CRIP-P131 cells with the retrovirus produced by the BOSC 23 cells was also the same as previously described for pRx-crmA-bsr. In this case, however, Ψ CRIP-P131 cells infected with the retrovirus
25 derived from pRx-Bcl-xl-bsr were selected with blasticidin. For the purpose of selection, Ψ CRIP producer cells infected with the retrovirus derived from the BOSC 23 cells were cultured for 7 days in Dulbecco's medium (complete) containing 10 μ g/ml of blasticidin (Funakoshi). Thus, a Ψ CRIP-P131 cell line infected with the
30 retrovirus derived from pRx-Bcl-xl-bsr was generated and named Ψ CRIP-P131/Bcl-xl.

e) Establishment of the 293/Bcl-xl cell line:
The method for infecting 293 cells of the parent cell
35 line with the retrovirus produced by Ψ CRIP-P131/Bcl-xl cells was the same as previously described for the

establishment of the 293/crmA cell line. In this case, however, 293 cells infected with the retrovirus were selected with blasticidin. For the purpose of selection, 293 producer cells infected with the retrovirus
5 derived from Ψ CRIP-P131/Bcl-xl cells were cultured for 7 days in Dulbecco's medium (complete) containing 10 μ g/ml of blasticidin (Funakoshi). Thus, a 293 cell line infected with the retrovirus derived from Ψ CRIP-P131/Bcl-xl was established and named the 293/Bcl-xl cell
10 line.

Example 3: Generation of an apoptosis-resistant virus-sensitive cell line 293/Bcl-2

a) The cDNA clone of Bcl-2 used in this example was obtained from the plasmid pB4 bcl-2a. The plasmid
15 pB4 bcl-2a was generously supplied by Dr. Tsujimoto, Department of Medicine, Osaka University. The base sequence of an *Eco*RI fragment thereof is shown as SEQ ID NO:4.

b) Construction of pRx-Bcl 2-i-hCD 25:

20 This *Eco*RI fragment was made blunt-ended with T4 DNA polymerase (purchased from NEB Co.) and integrated into the blunt-ended *Cla*I and *Not*I sites of the plasmid pRx-ires-hCD 25 to generate pRx-Bcl 2-i-hCD 25. The base sequence thereof is shown as SEQ ID NO:5.

25 In this sequence, a base sequence consisting of a large number of "A"s arranged on the outside of the LTR of the retrovirus represents an unidentified sequence part for convenience' sake. The plasmid pRx-ires-hCD 25 used in this example is described in Shino-
30 ura and Hamada, "Retroviruses", pp. 58-62; and Saito and Sugano (eds.), "An Extra Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodosha.

e) Generation of Ψ CRIP-P131/Bcl-2:

35 A basic method for gene transfer by use of a retrovirus vector is described in Shinoura and Hamada,

"Retroviruses", pp. 58-62; and Saito and Sugano (eds.), "An Extra Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodosha. For the Ψ CRIP-P131 cell line, see the
5 aforementioned article by Wakimoto H. et al. Also in this example, the method described in the above references was basically employed to establish a cell line capable of expressing Bcl-2 on a high level. However, the method employed in this example was based on selec-
10 tion by the expression of human CD 25.

The transfection of BOSC 23 cells with the plasmid DNA of pRx-Bcl 2-i-hCD 25 was performed in the same manner as previously described for pRx-crmA-bsr. The method for infecting Ψ CRIP-P131 cells with the retro-
15 virus produced by the BOSC 23 cells was also the same as previously described for pRx-crmA-bsr. In this case, however, Ψ CRIP-P131 cells infected with the retrovirus derived from pRx-Bcl 2-i-hCD 25 were selected by staining the cells with human CD 25 antibody (FITC-labelled
20 anti-Tac; purchased from Pharmingen Co.). Then, using a cell sorter (FACStar; Becton-Dickinson Co.), CD 25-positive cells were selected in the usual manner. Thus, a Ψ CRIP-P131 cell line infected with the retrovirus derived from pRx-Bcl 2-i-hCD 25 was generated and named
25 Ψ CRIP-P131/Bcl 2.

d) Establishment of the 293/Bcl-xl cell line:

The method for infecting 293 cells of the parent cell line with the retrovirus produced by Ψ CRIP-P131/Bcl 2 cells was the same as previously described for the
30 establishment of the 293/crmA cell line. In this case, however, 293 cells infected with the retrovirus were selected by staining the cells with human CD 25 antibody (FITC-labelled anti-Tac; purchased from Pharmingen Co.). The method for selecting CD 25-positive cells was the
35 same as described above for the selection of Ψ CRIP-P131/Bcl 2. Thus, a 293 cell line infected with the retro-

virus derived from Ψ CRIP-P131/Bcl 2 was established and named the 293/Bcl 2 cell line.

Example 4: Construction of a pAx cosmid pAxCAhFAS

a) Preparation of hFAS cDNA:

5 hFAS cDNA was prepared in the following manner.
Cells of the human monocyte-derived cell line THP1
(ATCC) purchased from ATCC were treated with 50 ng/ml of
a phorbol ester (PMA; purchased from Sigma Co.) for 24
hours, and mRNA was prepared from these cells in the
10 usual manner. Using this mRNA as a template, RT-PCR
(reverse transcription-polymerase chain reaction) was
performed in the usual manner to obtain about 1028 bp
cDNA. The primers used in this PCR (polymerase chain
reaction) were the following oligonucleotides which had
15 been prepared in our laboratory.

#457 CCGAATTCTCGAGCACCATGCTGGGCATCTGGACCCCTC
(SEQ ID NO:6)

#458 CCGAATTCTAGACCAAGCTTTGGATTTTCATTTCTGAAGTTTGA
(SEQ ID NO:7)

20 b) Confirmation of the base sequence of cDNA:

The *Eco*RI fragment of the resulting cDNA was
cloned into the *Eco*RI site of pBluescriptKS+ (pKS)
(purchased from Stratagene Co.). Thereafter, a clone
pKShFAS having a *Kpn*I site located upstream of the 5'
25 end of hFAS was used. The base sequence of the cDNA of
pKShFAS was determined according to the Sanger method
and confirmed to be identical to that reported in Gen-
Bank.

c) Construction of a plasmid pCEPhFAS:

30 A *Kpn*I/*Not*I fragment (about 1100 bp) was excised
from pKShFAS and subcloned into the *Kpn*I/*Not*I sites of
pCEP 4 (purchased from Invitrogen Co.) to generate
pCEPhFAS.

d) Construction of the plasmid pCAhFAS:

35 An *Eco*RI fragment (about 1028 bp) containing
hFAS was excised from pCEPhFAS and subcloned into the

EcoRI site of pCAcc to generate pCAhFAS. For pCAcc, see Niwa, H., Yamamura, K., and Miyazaki, J. (1991), *Gene* (Amst.) 108, 193-200; and Yoshida Y et al., *Biochem. Biophys. Res. Commun.* 230, 426-430 (1997).

5 e) pAxCAhFAS:

A *ClaI* fragment (3.3 kbp) was excised from pCAhFAS and subcloned into the *ClaI* site of pAdexlcw. A clone having the "leftward" direction was selected and regarded as pAxCAhFAS. For the pAx cosmid, see, for
10 example, Sato et al., *Methods for the Generation of Recombinant Adenoviruses*, pp. 27-42; Saito and Sugano (eds.), "An Extra Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodosha; or Miyake, S., Makimura, M.,
15 Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. (1996), *Proc. Natl. Acad. Sci. USA* 93, 1320-1324.

Example 5: Construction of a pAx cosmid pAxCAhFasLig

A cosmid pAxCAhFasLig was constructed in sub-
20 stantially the same manner as described above for pAxCAhFAS. The cDNA of hFasLig (human FAS ligand) used in this example was derived from the plasmid pFLNL4 generously supplied by Dr. E. Mita, First Department of Internal Medicine, Osaka University [Mita E, *Biochem.*
25 *Biophys. Res. Commun.* 204(2), 468-474 (1994)]. The base sequence of the aforesaid cDNA is shown in SEQ ID NO:8.

A *HindIII/NsiI* fragment was excised from this plasmid and subcloned into the *HindIII/PstI* sites of pBluescriptSKII (hereinafter abbreviated as pSK; purchased from Stratagene Co.) to generate pSKII+FasLig.
30 Then, a DNA fragment containing FasLig was excised from pSKII+FasLig by *ClaI/XbaI* cleavage, made blunt-ended with T4 DNA polymerase, and ligated to the *EcoRI* site of pCAcc which had been made blunt-ended with T4 DNA poly-
35 merase. Moreover, the direction of the fragment was confirmed to generate pCAhFasLig. Thereafter, a DNA

fragment containing FasLig was excised from pCAhFasLig by *Cla*I cleavage, and cloned into the *Cla*I site of pAxcw to generate pAxCahFasLig.

Example 6: Construction of a pAx cosmid pAxCahFLICE
(Caspase-8)

5 A cosmid pAxCahFLICE (Caspase-8) was constructed in substantially the same manner as described above for pAxCahFAS. The cDNA of hFLICE (Caspase-8) used in this example was that described in Muzio et al., Cell 85,
10 817-827 (1996).

Specifically, pcDNA 3 containing the cDNA of hFLICE (Caspase-8) was obtained from Dixit VM et al. A DNA fragment containing FLICE was excised from this plasmid by *Hind*III/*Not*I cleavage, made blunt-ended with
15 T4 DNA polymerase, and ligated to the *Eco*RI site of pCAcc which had been made blunt-ended with T4 DNA polymerase. Moreover, the direction of the fragment was confirmed to generate pCAhFLICE. Then, a DNA fragment containing FLICE was excised from pCAhFLICE by *Cla*I
20 cleavage, and cloned into the *Cla*I site of pAxcw to generate pAxCahFLICE.

Example 7: Construction of a pAx cosmid pAxCahBcl-xs

A cosmid pAxCahBcl-xs was constructed in substantially the same manner as described above for
25 pAxCahFAS. The cDNA of pAxCahBcl-xs used in this example was pSKIIhBcl-xl generously supplied by Dr. Andy Minn, University of Chicago, Gwen Knapp Center for Lupus and Immunology Research (Fax 773-702-1576) for the cDNA of Bcl-xl.

30 A plasmid pCA-Bcl-xs was generated by excising an *Eco*RI fragment (about 600 bp) containing hBcl-xs from pSKIIhBcl-xs and subcloning this fragment into the *Eco*RI site of pCAcc. Then, a DNA fragment containing CA-Bcl-xs was excised from pCA-Bcl-xs and cloned into the *Cla*I
35 site of pAxcw to generate pAxCah-Bcl-xs.

Example 8: Construction of a pAx cosmid pAxCAhFADD

A cosmid pAxCAhFADD was constructed in substantially the same manner as described above for pAxCAhFAS. The cDNA of pAxCAhFADD used in this example was that
5 described in Muzio et al., Cell 85, 817-827 (1996).

Specifically, pcDNA 3 containing the cDNA of hFADD was obtained from Dixit VM et al. A DNA fragment (about 700 bp) containing hFADD was excised from this plasmid by *HindIII/XhoI* cleavage, made blunt-ended with
10 T4 DNA polymerase, and ligated to the *EcoRI* site of pCacc which had been made blunt-ended with T4 DNA polymerase. Moreover, the direction of the fragment was confirmed to generate pCAhFADD. Then, a DNA fragment (about 3 kbp) containing CAhFADD was excised from
15 pCAhFADD by *ClaI* cleavage, and cloned into the *ClaI* site of pAxcw to generate pAxCAhFADD.

Example 9: Generation of an Ax recombinant adenovirus AxCAhFAS

a) The DNA of the cosmid pAxCAhFAS was prepared
20 in the usual manner and used to transfect 293/crmA cells. Then, clones of the desired adenovirus AxCAhFAS were selected in the usual manner. For the method for generating the adenovirus, see, for example, Sato et al., Methods for the Generation of Recombinant Adenoviruses, pp. 27-42; Saito and Sugano (eds.), "An Extra
25 Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodoshita; or Miyake, S., Makimura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I.
30 (1996), Proc. Natl. Acad. Sci. USA 93, 1320-1324.

b) The function of the resulting adenovirus AxCAhFAS was examined in the following manner.

(Procedure) Using 293/crmA cells, a tertiary seed of the recombinant adenovirus AxCAhFAS was prepared
35 and used to infect human glioma cells of the U251 cell line (generously supplied by NCI, U.S.A.) at an moi of

100. After 2 days, the expression of FAS was confirmed by FACS. FACS was performed according to the standard method described, for example, in K. Hanada et al., J. Leukocyte Biology 60, 181-190, 1996. As a control, U251
5 cells were infected with AxCALacZ at an moi of 100. Anti-human CD 95-FITC (Pharmingen) was used as the primary antibody in an amount of 10 μ l per 1×10^6 cells, and anti-Leu2a (anti-CD 8)-FITC (Becton Dickinson Immunocytometry Systems, San Jose, CA) was used as a
10 control antibody in an amount of 10 μ l per 1×10^6 cells.

(Results) The results are shown in Fig. 2. It was confirmed that the expression of FAS in U251 cells was very greatly enhanced by infection with the recombi-
15 nant adenovirus AxCAhFAS (peak 4). Peak 1 shows U251 cells stained with the control antibody. Peak 2 shows uninfected U251 cells stained with anti-human CD 95-FITC (Pharmingen). In U251 cells, a slight expression of FAS is observed. Peak 3 shows U251 cells infected with
20 AxCALacZ as a control. Infection with the simple adenovirus causes a slight change in the expression level of FAS, but this change is very slight as compared with the change shown by peak 4. The AxCALacZ adenovirus used in this example is one commonly used as a control, and is
25 described, for example, in Nakamura et al., Cancer Res. 54, 5747-5760, 1994. These results demonstrate that an intense expression of FAS is achieved by infection with the recombinant adenovirus AxCAhFAS.

30 Example 10: Generation of an Ax recombinant adenovirus AxCAhFasLig

a) The DNA of the cosmid pAxCAhFasLig was prepared in the usual manner and used to transfect 293/crma cells. Then, clones of the desired adenovirus AxCAhFasLig were selected in the usual manner. The
35 method for generating the adenovirus was the same as previously described for the generation of AxCAhFAS.

b) The function of the resulting adenovirus AxCAhFasLig was examined in the following manner.

(Procedure) Using 293/crmA cells, a tertiary seed of the recombinant adenovirus AxCAhFasLig was prepared and used to infect human glioma cells of the U373 cell line (purchased from ATCC) at an moi of about 100. After 2 days, the expression of FAS ligand was confirmed by FACS. FACS was performed according to the standard method described, for example, in K. Hanada et al., J. Leukocyte Biology 60, 181-190, 1996. Anti-Fas ligand (human)-biotin (Sumitomo Electric, Yokohama, Japan) was used as the primary antibody in an amount of 5 μ l per 1×10^6 cells, and streptoavidin-PE (Pharmin-gen, San Diego, CA) was used as the secondary antibody in an amount of 0.5 μ l per 1×10^6 cells.

(Results) The results are shown in Fig. 3. It was confirmed that the expression of FAS ligand in U373 cells was induced by infection with the FAS ligand adenovirus (AxCAhFasLig). Peak 1 shows the results of analysis of control U373 cells, and peak 2 shows the results of analysis of U373 cells infected with the FAS ligand adenovirus (AxCAhFasLig). These results demonstrate that an intense expression of FAS ligand is achieved by infection with the recombinant adenovirus AxCAhFasLig.

Example 11: Generation of an Ax recombinant adenovirus AxCAhBcl-xs

a) The DNA of the cosmid pAxCAhBcl-xs was prepared in the usual manner and used to transfect 293/crmA cells. Then, clones of the desired adenovirus AxCAhBcl-xs were selected in the usual manner. The method for generating the adenovirus was the same as previously described for the generation of AxCAhFAS.

Example 12: Generation of an Ax recombinant adenovirus AxCAhFADD

a) The DNA of the cosmid pAxCAhFADD was pre-

pared in the usual manner and used to transfect 293 cells. Then, clones of the desired adenovirus AxCAhFADD were selected in the usual manner. The method for generating the adenovirus was the same as previously
5 described for the generation of AxCAhFAS. In the case of AxCAhFADD, viruses up to the secondary seed could be prepared by using 293 cells of the parent cell line instead of 293/crmA cells. However, for viruses of the tertiary seed and further, 293 cells of the parent cell
10 line failed to achieve a sufficiently high viral titer. Accordingly, for viruses of the tertiary seed and further, a virus suspension was prepared by using 293/crmA cells. (Thus, with respect to an adenovirus capable of expressing an apoptosis-associated gene, it may happen
15 that, even if the recombinant virus can be generated by using ordinary 293 cells, the preparation of a large amount of the virus induces apoptosis in 293 cells of the parent cell line and fails to achieve a sufficiently high viral titer. In such a case, it is expected that
20 use of the 293/crmA cell line or the like permits the preparation of a large amount of the virus. This is also a useful application of the 293/crmA cell line and like cell lines disclosed herein.) For the definition of secondary and tertiary seed viruses, see, for exam-
25 ple, Sato et al., Methods for the Generation of Recombinant Adenoviruses, pp. 27-42; or Saito and Sugano (eds.), "An Extra Issue of Experimental Medicine: Experimental Methods for Gene Transfer and Expression Analysis", 1997, Yodosha.

30 b) The functions of the resulting adovirus AxCAhFADD were confirmed by the fact that, when a subline of the human glioma cell U251 (i.e., U251-FAS-H which had been established in out laboratory) was infected therewith at MOI = 5, a marked cell death (apo-
35 ptosis) was induced. Fig. 4 shows the state of the subline of U251 (U251-FAS-H) two days after infection

with AxCAhFADD. Although U251 cells inherently grow while adhering to a plastic plate, most of the cells infected with AxCAhFADD were found floating on the surface. The functions of the adenovirus AxCAhFADD were also confirmed by infecting the human glioma cell U373 therewith at MOI = 100 and subjecting the proteins extracted therefrom on the second day to western blot analysis. Fig. 5 shows the results of western blot analysis of the proteins extracted from uninfected control U373 cells (lane 1), control U373 cells infected with AxCA-LacZ at MOI = 100 (lane 2), and U373 cells infected with AxCAhFADD at MOI = 100 (lane 3). These analyses were carried out according to an ordinary procedure using a commercially available anti-FADD antibody.

Other References:

Unless otherwise indicated, the general methods employed in the practice of the present invention are the standards methods described in the following protocols.

1. Coligan JE et al. (eds.), Current Protocols in Immunology, published by John Wiley and Sons, Inc.
2. Ausubel FM et al. (eds.), Current Protocols in Molecular Biology, published by John Wiley and Sons, Inc.
3. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd. ed., 1989, Cold Spring Laboratory Press, New York.

Effects of the Invention

According to the present invention, the generation of adenovirus vectors capable of expressing apoptosis-associated genes, which has been impossible in the prior art, can be achieved by providing, for example, an apoptosis-resistant 293 producer cell line and using it.

The recombinant adenoviruses capable of apoptosis-associated genes, which are generated in the above-described manner, can be applied to the treatment of various diseases.

5 Moreover, the method disclosed herein is believed to be useful in the generation of AxCA-(objective gene) adenoviruses capable of expressing various other apoptosis-associated genes and cell cycle-associated genes on a high level.

10 It is a matter of course that the usefulness of this method is not limited to 293/crma.

 Even if various other apoptosis resistance genes such as bcl-2, bcl-xs, FLIP (homo sapiens FLICE-like inhibitory protein, short form and long form; Irmeler et al., Nature 388, 190-195, 1997) and ILP (IAP-like protein ILP; Duckett et al., EMBO J. 15(11), 2685-2694, 1996) are introduced (stably or transiently) into 293 cells, the resulting cells are believed to be useful in the generation of AxCA-(objective gene) adenoviruses
15 capable of expressing various other apoptosis-associated genes (such as FAS, FAS-Lig and FLICE) and cell cycle-associated genes on a high level.

 Similarly, it is expected that the generation of viruses other than adenoviruses, and other microorganisms
25 or their products (e.g., proteins), which has been difficult because of their high cytotoxicity to host cells, may become possible. This method can be applied to various fields including the generation of vectors for gene therapy and the preparation of vaccines against
30 viruses and other microorganisms or their products (e.g., proteins).

 Furthermore, the AxCA-(objective gene) adenoviruses capable of expressing various apoptosis-associated genes and cell cycle-associated genes on a high level,
35 which are generated by the method disclosed herein, are believed to be useful in the following cases:

(1) Induction of apoptosis by gene transfer.

(1-1) Application to the treatment of cancer by destroying cancer cells selectively. Apoptosis induction therapy for cancer cells.

5 (1-2) Utilization in the treatment of autoimmune diseases and graft rejection reactions. Apoptosis induction therapy for immunocompetent cells.

(1-3) Apoptosis induction therapy for inflammatory cells in inflammatory diseases.

10 (2) Utilization of the inhibition of apoptosis by gene transfer. In this case, it may be possible to inhibit harmful apoptotic reactions, for example, by expressing bcl-2, bax (antisense or dominant-negative), FAS (antisense or dominant-negative), FADD (antisense or
15 dominant-negative) or the like on a high level.

(2-1) In fulminant hepatitis, the inhibition of apoptosis by gene transfer to hepatic cells may be utilized to minimize a severe necrosis of hepatic cells and thereby save the patient's life.

20 (2-2) The prevention and treatment of autoimmune diseases, graft rejection reactions and other diseases in which harmful apoptosis is considered to be occur.

(2-3) The prevention and treatment of inflammatory diseases and other diseases in which harmful apoptosis is considered to be occur.
25

(2-4) Nervous diseases. Apoptosis may be controlled to promote the regeneration and differentiation of nerves. Moreover, harmful apoptosis of nerve cells,
30 which is observed in traumata, angiopathy and degenerative diseases (e.g., Alzheimer's disease), may be controlled to arrest or treat these nervous diseases.


CLAIMS

1. An apoptosis-resistant virus-sensitive cell line having an apoptosis resistance gene introduced thereinto.
2. A cell line as claimed in claim 1 wherein the apoptosis resistance gene is selected from the group consisting of the *crmA*, *bcl-2*, *bcl-xl*, *FLIP*, *survivin*, *IAP* and *ILP* genes.
3. A cell line as claimed in claim 1 or 2 wherein the virus-sensitive cell line is the 293 cell line derived from a human fetal kidney.
4. A cell line as claimed in any of claims 1 to 3 wherein the virus is selected from the group consisting of viruses belonging to the families *Adenoviridae*, *Retroviridae*, *Parvoviridae*, *Herpesviridae*, *Poxviridae*, *Papovaviridae* and *Hepadnaviridae*.
5. A cell line as claimed in claim 3 wherein the virus is a human adenovirus belonging to the family *Adenoviridae*.
6. A method for the generation of a recombinant virus containing an apoptosis-associated gene which comprises the steps of:
 - (A) providing an apoptosis-resistant virus-sensitive cell line having an apoptosis resistance gene introduced thereinto;
 - (B) transfecting cells of the cell line of step (A) with a virus (or expression vector) containing an apoptosis-associated gene in combination with a helper virus, if necessary; and
 - (C) culturing the transfected cells of step (B) to produce a recombinant virus containing the apoptosis-associated gene.
7. A method as claimed in claim 5 wherein the apoptosis-associated gene is selected from the group consisting of the *FAS*, *Fas Lig*, *FLICE* and *bcl-xs* genes.


8. A method as claimed in claim 6 or 7 wherein the virus-sensitive cell line is the 293 cell line derived from a human fetal kidney.
9. A method as claimed in any of claims 6 to 8 wherein the virus is selected from the group consisting of viruses belonging to the families *Adenoviridae*, *Retroviridae*, *Parvoviridae*, *Herpesviridae*, *Poxviridae*, *Papovaviridae* and *Hepadnaviridae*.
10. A recombinant virus containing an apoptosis-associated gene which is generated by a method as claimed in any of claims 6 to 9.
11. A recombinant adenovirus containing an apoptosis-associated gene.
12. A recombinant adenovirus as claimed in claim 11 wherein the apoptosis-associated gene is selected from the group consisting of the FAS (CD 95), Fas Lig, FLICE, Bax, bcl-2, bcl-2 antisense and bcl-xs genes.

Fig. 1

A



B



2 / 4

Fig. 2






Fig. 3




3 / 4

Fig. 4



4 / 4

Fig. 5



1/18

SEQUENCE LISTING

<110> RPR Gencell Asia/Pacific Inc.

<120> VIRAL VECTOR SYSTEM CAPABLE OF EXPRESSING AN APOPTOSIS-
ASSOCIATED GENE

<130> K-2Gencell

<150> JP 9-259235

<151> 1997-09-08

<160> 8

<170> WordPerfect Ver. 7.0

<210> 1

<211> 7797

<212> DNA

<213> cowpox virus

<220>

<222> 2036-3215

<400> 1

ctcgaggagc ttggcccatt gcatacgttg tatccatata ataatatgta catttatatt	60
ggctcatgtc caacattacc gccatgttga cattgattat tgactagtta ttaatagtaa	120
tcaattacgg ggtcattagt tcatagccca tatatggagt tccgcgttac ataacttacg	180
gtaaatggcc cgcctggctg accgcccac gacccccgcc cattgacgtc aataatgacg	240
tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggactattta	300
cggtaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac gccccctatt	360
gacgtcaatg acggtaaagt gcccgcctgg cattatgccc agtacatgac cttatgggac	420
tttcctactt ggcagtacat ctacgtatta gtcacgcta ttaccatgct agagaaccat	480
cagatgtttc cagggtgccc caaggacctg aaatgaccct gtgccttatt tgaactaacc	540
aatcagttcg cttctcgctt ctgttcgcgc gcttctgctc cccgagctca ataaaagagc	600
ccacaacccc tcactegggg cgccagtcct ccgattgact gagtcgccc ggtacccgtg	660
tatccaataa accctcttgc agttgcatcc gacttgtggt ctgctgttc cttgggaggg	720

2/18

tctcctctga	gtgattgact	acccgtcagc	gggggtcttt	catttggggg	ctcgtccggg	780
atcgggagac	ccctgcccag	ggaccaccga	cccaccaccg	ggaggtaagc	tggccagcaa	840
cttatctgtg	tctgtccgat	tgtctagtgt	ctatgactga	ttttatgcgc	ctgcgtcggg	900
actagttagc	taactagctc	tgtatctggc	ggacccgtgg	tggaactgac	gagttcggaa	960
cacccggccg	caaccctggg	agacgtccca	gggacttcgg	gggccgtttt	tgtggcccga	1020
cctgagteca	aaaatcccga	tcgttttggg	ctctttgggtg	caccccccta	ataggaggga	1080
tatgtggttc	tggtaggaga	cgagaacct	aaacagttcc	cgcctccgtc	tgaatttttg	1140
ctttcggttt	gggaccgaag	ccgcgccggc	cgtcttgtct	gctgcagcat	cgttctgtgt	1200
tgtctctgtc	tgactgtgtt	tctgtatttg	tctgaaaatt	agggccagac	tgttaccact	1260
cccttaagtt	tgaccttagg	tacttgaaa	gatgtcgagc	ggatcgctca	caaccagtcg	1320
gtagatgtca	agaagagacg	ttgggttacc	ttctgctctg	cagaatggcc	aacctttaac	1380
gtcggtatggc	cgcgagacgg	cacctttaac	cgagacctca	tcaccaggt	taagatcaag	1440
gtcttttcac	ctggcccgcg	tggacacca	gaccaggtcc	cctacatcgt	gacctgggaa	1500
gccttggtct	ttgaccccc	tccctgggtc	aagcccttg	tacaccctaa	gcctccgcct	1560
cctcttctc	catccgcccc	gtctctcccc	cttgaacctc	ctcgttcgac	cccgctcga	1620
tcctcccttt	atccagccct	cactccttct	ctaggcgccc	atatgagatc	ttatatgggg	1680
cacccccgcc	ccttgtaaac	ttccctgacc	ctgacatgac	aagagttact	aacagccct	1740
ctctccaagc	tcacttacag	gctctctact	tagtccagca	cgaagtctgg	agacctctgg	1800
cggcagccta	ccaagaacaa	ctggaccgac	cgggtgtacc	tcacccttac	cgagtcggcg	1860
acacagtgtg	ggtccgcccga	caccagacta	agaacctaga	acctcgctgg	aaaggacctt	1920
acacagtcct	gctgaccacc	cccaccgccc	tcaaagtaga	cggcatcgca	gcttggtatac	1980
acgccgccc	cgtgaaggct	gccgaccccg	ggggtggacc	atcctctaga	ctgccatgga	2040
tatcttcagg	gaaatcgcat	cttctatgaa	aggagagaat	gtattcattt	ctccaccgtc	2100
aatctcgtca	gtattgacaa	tactgtatta	tggagcta	ggatccactg	ctgaacagct	2160
atcaaaatat	gtagaaaagg	aggcggacaa	gaataaggat	gatatctcat	tcaagtcctat	2220
gaataaagta	tatgggcgat	attctgcagt	gtttaaagat	tcctttttga	gaaaaattgg	2280
agataatttc	caaactgttg	acttcactga	ttgtcgact	gtagatgcga	tcaacaagtg	2340
tgttgatata	ttcactgagg	ggaaaattaa	tccactattg	gatgaaccat	tgtctccaga	2400
tacctgtctc	ctagcaatta	gtgccgtata	ctttaaagca	aaatgggtga	tgccatttga	2460
aaaggaattt	accagtgatt	atccctttta	cgtatctcca	acggaaatgg	tagatgtaag	2520
tatgatgtct	atgtacggcg	aggcatttaa	tcacgcatct	gtaaaagaat	cattcggcaa	2580
cttttcaatc	atagaactgc	catatgttgg	agatactagt	atgggtgtaa	ttcttccaga	2640
caatattgat	ggactagaat	ccatagaaca	aatctaaca	gatacaaatt	ttaagaaatg	2700
gtgtgactct	atggatgcta	tgtttatcga	tgtgcacatt	cccaagttaa	aggtaacagg	2760
ctcgtataat	ctggtggatg	cgtagtaaaa	gttgggactg	acagaggtgt	tcggttcaac	2820
tggagattat	agcaatatgt	gtaattcaga	tgtgagtgtc	gacgctatga	tccacaaaac	2880

4/18

aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5100
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5160
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5220
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5280
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5340
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5400
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5460
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5520
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	5580
gaattggtcg	aagcttggcg	agatttttcag	gagctaagga	agctaaaatg	gagaaaaaaa	5640
tacttgata	taccaccgtt	gatatatccc	aatggcatcg	taaagaacat	tttgaggcat	5700
ttcagtcagt	tgtcfaatgt	acctataacc	agaccgttca	gctgcattaa	tgaatcggcc	5760
aacgcgcggg	gagaggcggt	ttgcgtattg	ggcgctcttc	cgcttcctcg	ctcactgact	5820
cgctgcgctc	ggtcgttcgg	ctgcggcgag	cggatatcagc	tcactcaaag	gcggtataac	5880
ggttatccac	agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	5940
aggccaggaa	ccgtaaaaag	gccgcgttgc	tggcggtttt	ccataggctc	cgccccctg	6000
acgagcatca	caaaaatcga	cgctcaagtc	agagggtggcg	aaacccgaca	ggactataaa	6060
gataccaggc	gtttccccct	ggaagctccc	tcgtgcgctc	tcctgtttccg	accctgcgcg	6120
ttaccggata	cctgtccgcc	tttctccctt	cgggaagcgt	ggcgctttct	caatgctcac	6180
gctgtaggta	tctcagttcg	gtgtaggtcg	ttcgctccaa	gctgggctgt	gtgcacgaac	6240
ccccgttca	gcccgaaccg	tgcgccttat	ccggtaacta	tcgtcttgag	tccaacccgg	6300
taagacacga	cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	6360
atgtaggcgg	tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagga	6420
cagtatttgg	tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggttagct	6480
cttgatccgg	caaacaacc	accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	6540
ttacgcgcag	aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	6600
ctcagtggaa	cgaaaactca	cgtaaggga	ttttggtcat	gagattatca	aaaaggatct	6660
tcacctagat	ccttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	6720
aaacttggtc	tgacagttac	caatgcttaa	tcagtgaggc	acctatctca	gcgatctgtc	6780
tatttcgttc	atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	6840
gcttaccatc	tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	6900
atttatcagc	aataaaccag	ccagccggaa	gggccgagcg	cagccgtggt	cctgcaactt	6960
tatccgcctc	catccagtct	attaattgtt	gccgggaagc	tagagtaagt	agttcgccag	7020
ttaatagttt	gcgcaacgtt	gttgccattg	ctacaggcat	cgtggtgtca	cgtcgtcgt	7080
ttggtatggc	ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	tgatccccca	7140
tgttgtgcaa	aaaagcggtt	agctccttcg	gtcctccgat	cgttgtcaga	agtaagttgg	7200

5/18

ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat 7260
 ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgtg 7320
 tgcggcgacc gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca 7380
 gaactttaaa agtgcctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct 7440
 taccgctgtt gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat 7500
 cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa 7560
 agggaataag ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt 7620
 gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa 7680
 ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac gtctaagaaa 7740
 ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc tttcgtc 7797

<210> 2

<211> 6644

<212> DNA

<220>

<222> 1-6644

<400> 2

ctcgaggagc ttggcccatt gcatacgttg tatccatatac ataatatgta catttatatt 60
 ggctcatgtc caacattacc gccatgttga cattgattat tgactagtta ttaatagtaa 120
 tcaattacgg ggtcattagt tcatagccca tatatggagt tccgcgttac ataacttacg 180
 gtaaattggc cgcctggctg accgccaac gacccccgcc cattgacgtc aataatgacg 240
 tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggactattta 300
 cggtaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac gcccctatt 360
 gacgtcaatg acggtaaatg gcccgctgg cattatgccc agtacatgac cttatgggac 420
 tttcctactt ggcagtacat ctacgtatta gtcacgtc taacctatgt agagaacctat 480
 cagatgtttc cagggtgccc caaggacctg aaatgacct gtgccttatt tgaactaacc 540
 aatcagttcg cttctcgctt ctgttcgcgc gcttctgtc cccgagctca ataaaagagc 600
 ccacaacccc tactcgggg cgccagtcct ccgattgact gagtcgccc ggtaccgctg 660
 tatccaataa accctcttgc agttgcatcc gacttgtggt ctgctgttc cttgggaggg 720
 tctcctctga gtgattgact acccgtcagc ggggtcttt catttggggg ctgctccggg 780
 atcgggagac cctgcccag ggaccaccga cccaccacc ggaggtaagc tggccagcaa 840
 cttatctgtg tctgtccgat tgtctagtgt ctatgactga ttttatgcgc ctgcgtcggt 900
 actagttagc taactagctc tgtatctggc ggaccgtgg tggaactgac gagttcggaa 960
 caccggccg caaccctggg agacgtccca gggacttcgg gggcgtttt tgtggcccg 1020
 cctgagtcca aaaatccga tcgttttgga ctctttggtg caccccccta ataggaggga 1080

6/18

tatgtggttc	tggtaggaga	cgagaaccta	aaacagttcc	cgcctccgtc	tgaatttttg	1140
ctttcggttt	gggaccgaag	ccgcgccgcg	cgtcttgtct	gctgcagcat	cgttctgtgt	1200
tgtctctgtc	tgacttgtgt	tctgtatttg	tctgaaaatt	agggccagac	tgttaccact	1260
cccttaagtt	tgaccttagg	tacttgaaa	gatgtcgagc	ggatcgctca	caaccagtcg	1320
gtagatgtca	agaagagacg	ttgggttacc	ttctgctctg	cagaatggcc	aacctttaac	1380
gtcggatggc	cgcgagacgg	cacctttaac	cgagacctca	tcaccaggt	taagatcaag	1440
gtcttttcac	ctggccccga	tggacaccca	gaccaggtcc	cctacatcgt	gacctgggaa	1500
gccttggttt	ttgaccccc	tccctgggtc	aagccctttg	tacaccctaa	gcctccgctt	1560
cctcttcttc	catccgcccc	gtctctcccc	cttgaacctc	ctcgttcgac	cccgcctega	1620
tcctcccttt	atccagccct	cactccttct	ctaggcgccc	atatgagatc	ttatatgggg	1680
cacccccgcc	ccttgtaaac	ttccctgacc	ctgacatgac	aagagttact	aacagccctt	1740
ctctccaagc	tcacttacag	gtctcttact	tagtcacgca	cgaagtctgg	agacctctgg	1800
cggcagccta	ccaagaacaa	ctggaccgac	cgggtgtacc	tcacccttac	cgagtcggcg	1860
acacagtgtg	ggtccgcca	caccagacta	agaacctaga	acctcgctgg	aaaggacctt	1920
acacagtcct	gctgaccacc	cccaccgccc	tcaaagtaga	cggcatcgca	gcttgatac	1980
acgccgcccc	cgtgaaggct	gccgaccccg	ggggtggacc	atcctctaga	ctgccggatc	2040
ccagtgtggt	ggtagggaat	tcgagctcgg	taccgggggg	cgcccgcat	ccttaattaa	2100
gcgccgcggg	taacaattgt	taactaacta	actaagctag	caacggtttc	cctctagcgg	2160
gatcaattcc	ccctctccct	ccccccccc	taacgttact	ggccgaagcc	gcttggaata	2220
aggccgggtg	gcgtttgtct	atatgttatt	ttccaccata	ttgccgtctt	ttggcaatgt	2280
gagggcccg	aaacctggcc	ctgtcttctt	gacgagcatt	cctaggggtc	tttccctctt	2340
cgccaaagga	atgcaaggct	tgttgaaatg	cgtgaaggaa	gcagttcctc	tggaagcttc	2400
ttgaagacaa	acaacgtctg	tagcgacctt	ttgcaggcag	cggaaccccc	cacctggcga	2460
cagggtgcctc	tgcggccaaa	agccacgtgt	ataagataca	cctgcaaagg	cggcacaacc	2520
ccagtgccac	gttgtgagtt	ggatagttgt	ggaaagagtc	aaatggctct	cctcaagcgt	2580
attcaacaag	gggctgaagg	atgccagaa	ggtaccccat	tgtatgggat	ctgatctggg	2640
gcctcggtgc	acatgcttta	catgtgttta	gtcgaggtta	aaaaacgtct	aggccccccg	2700
aaccacgggg	acgtggtttt	cctttgaaaa	acacgataat	accatggtca	tgaaaacatt	2760
taacatttct	caacaagatc	tagaattagt	agaagtagcg	acagagaaga	ttacaatgct	2820
ttatgaggat	aataaacatc	atgtgggagc	ggcaattcgt	acgaaaacag	gagaaatcat	2880
ttcggcagta	catattgaag	cgtatatagg	acgagtaact	gtttgtgcag	aagccattgc	2940
gattggtagt	gcagtttcga	atggacaaaa	ggattttgac	acgattgtag	ctgttagaca	3000
cccttattct	gacgaagtag	atagaagtat	tcgagtggta	agtccttgtg	gtatgtgtag	3060
ggagttgatt	tcagactatg	caccagattg	ttttgtgtta	atagaaatga	atggcaagtt	3120
agtcaaaact	acgattgaag	aactcattcc	actcaaatat	acccgaaatt	aaaagtcgac	3180
gataaaataa	aagattttat	ttagtctcca	gaaaaagggg	ggaatgaaag	acccacacctg	3240

7/18

taggtttggc	aagctagctt	aagtaacgcc	atthttgcaag	gcatggaaaa	atacataact	3300
gagaatagag	aagttcagat	caaggtcagg	aacagatgga	acagctgaat	atgggccaaa	3360
caggatatct	gtggtaaagca	gttcctgccc	cggctcaggg	ccaagaacag	atggaacagc	3420
tgaatatggg	ccaaacagga	tatctgtggt	aagcagttcc	tgccccggct	cagggccaaag	3480
aacagatggt	ccccagatgc	ggtccagccc	tcagcagttt	ctagagaacc	atcagatggt	3540
tccagggtgc	cccaaggacc	tgaaatgacc	ctgtgcctta	tttgaactaa	ccaatcagtt	3600
cgcttctcgc	ttctgttcgc	gcgcttctgc	tccccgagct	caataaaaaga	gcccacaacc	3660
cctcactcgg	ggcgccagtc	ctccgattga	ctgagtcgcc	cgggtaccgc	tgtatccaat	3720
aaacctcttt	gcagttgcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3780
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3840
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3900
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3960
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4020
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4080
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4140
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4260
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4320
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4380
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaga	ttggtcgaag	4440
cttggcgaga	ttttcaggag	ctaaggaagc	taaaatggag	aaaaaatca	ctggatatac	4500
caccgttgat	atatcccaat	ggcatcgtaa	agaacatttt	gaggcatttc	agtcagttgc	4560
tcaatgtacc	tataaccaga	ccgttcagct	gcattaatga	atcggccaac	gcgcggggag	4620
aggcggtttg	cgtattgggc	gctcttcgcg	ttcctcgctc	actgactcgc	tgcgctcggt	4680
cgttcggtcg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacggg	tatccacaga	4740
atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaaggc	cagcaaaaagg	ccaggaaccg	4800
taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	agcatcacia	4860
aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccgcacagga	ctataaagat	accaggcggt	4920
tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgccgctta	ccggatacct	4980
gtccgccttt	ctcccttcgg	gaagcggtgg	gctttctcaa	tgctcacgct	gtaggtatct	5040
cagttcggtg	taggtcggtc	gctccaagct	gggctgtgtg	cacgaacccc	ccgttcagcc	5100
cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtcc	aaccgggtaa	gacacgactt	5160
atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	taggcggtgc	5220
tacagagttc	ttgaagtggg	ggcctaacta	cggctacact	agaaggacag	tatttggtat	5280
ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	5340
acaaaccacc	gctggtagcg	gtggtttttt	tgtttgcaag	cagcagatta	cgcgcagaaa	5400

8/18

```

aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaaacga 5460
aaactcacgt taagggattt tggatcatgag attatcaaaa aggatcttca cctagatcct 5520
tttaaattaa aaatgaagtt ttaaataaat cttaaagtata tatgagtaaa cttgggtctga 5580
cagttaccaa tgcttaataca gtgaggcacc tatctcagcg atctgtctat ttcgttcac 5640
catagttgcc tgactccccg tcgtgtagat aactacgata cgggaggggc taccatctgg 5700
ccccagtgt gcaatgatac cgcgagaccc acgtcaccg gctccagatt tatcagcaat 5760
aaaccagcca gccggaaggg ccgagcgag cegtgggtcct gcaactttat ccgcctccat 5820
ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg 5880
caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 5940
attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 6000
agcggttagc tccttcgggtc ctccgatcgt tgtcagaagt aagtggccg cagtgttatc 6060
actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 6120
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 6180
ttgtctctgc ccggcgtaaa tacgggataa taccgcgcca catagcagaa ctttaaaagt 6240
gtcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 6300
atccagttcg atgtaaccca ctctgtcacc caactgatct tcagcatctt ttactttcac 6360
Cagcgtttct gggtagcaaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 6420
gacacggaaa tgttgaatac tcatactctt cttttttcaa tattattgaa gcatttatca 6480
gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 6540
ggttcgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca ttattatcat 6600
gacattaacc tataaaaata ggcgtatcac gaggcccttt cgtc 6644

```

<210> 3

<211> 7373

<212> DNA

<213> homosapiens

<220>

<222> 2057-2790

<400> 3

```

ctcgaggagc ttggccatt gcatacgttg tatccatata ataatatgta catttatatt 60
ggctcatgtc caacattacc gccatgttga cattgattat tgactagtta ttaatagtaa 120
tcaattacgg ggtcattagt tcatagccca tatatggagt tccgcgttac ataacttacg 180
gtaaatggcc cgcctggctg accgccaac gacccccgcc cattgacgtc aataatgacg 240
tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggactattta 300
cggtaaactg cccacttgge agtacatcaa gtgtatcata tgccaagtac gccccctatt 360

```

9/18

gacgtcaatg	acggtaaagt	gccccgctgg	cattatgccc	agtacatgac	cttatgggac	420
tttctactt	ggcagtagat	ctacgtatta	gtcatcgcta	ttaccatgct	agagaacat	480
cagatgtttc	caggggtgccc	caaggacctg	aaatgaccct	gtgccttatt	tgaactaacc	540
aatcagttcg	cttctcgctt	ctgttcgcgc	gcttctgctc	cccgagctca	ataaaagagc	600
ccacaacccc	teactcgggg	cgccagtcct	ccgattgact	gagtcgcccc	ggtacccgtg	660
tatccaataa	accctcttgc	agttgcatcc	gacttgtggt	ctcgctgttc	cttgggaggg	720
tctcctctga	gtgattgact	acccgtcagc	gggggtcttt	catttggggg	ctcgccggg	780
atcgggagac	ccctgcccag	ggaccaccga	cccaccaccg	ggaggtaagc	tggccagcaa	840
Cttatctgtg	tctgtccgat	tgtctagtgt	ctatgactga	ttttatgcgc	ctgcgtcggg	900
actagttagc	taactagctc	tgtatctggc	ggacccgtgg	tggaaactgac	gagttcgga	960
cacccggccg	caaccctggg	agacgtccca	gggacttcgg	gggcccgttt	tgtggcccga	1020
cctgagtcca	aaaatcccga	tcgttttgga	ctcttttggt	caccccccta	ataggaggga	1080
tatgtggttc	tggtaggaga	cgagaaccta	aaacagtccc	cgcctccgtc	tgaatttttg	1140
ctttcggttt	gggaccgaag	ccgcgccgcg	cgtcttgtct	gctgcagcat	cgttctgtgt	1200
tgtctctgtc	tgactgtgtt	tctgtatttg	tctgaaaatt	agggccagac	tgttaccact	1260
cccttaagtt	tgaccttagg	tcactggaaa	gatgtcgagc	ggatcgctca	caaccagtcg	1320
gtagatgtca	agaagagacg	ttgggttacc	ttctgctctg	cagaatggcc	aacctttaac	1380
gtcggatggc	cgcgagacgg	cacctttaac	cgagacctca	tcaccaggt	taagatcaag	1440
gtcttttcac	ctggcccgcg	tggacacca	gaccaggccc	cctacatcgt	gacctgggaa	1500
gccttggttt	ttgaccccc	tccctgggtc	aagccctttg	tacaccctaa	gcctccgcct	1560
cctcttcctc	catccgcccc	gtctctcccc	cttgaacctc	ctcgttcgac	cccgcctcga	1620
tcctcccttt	atccagccct	cactccttct	ctaggcgccc	atatgagatc	ttatatgggg	1680
cacccccgcc	ccttgtaaac	ttccctgacc	ctgacatgac	aagagttact	aacagccctt	1740
ctctccaagc	tcacttacag	gctctctact	tagtccagca	cgaagtctgg	agacctctgg	1800
cggcagccta	ccaagaacaa	ctggaccgac	cggttggtacc	tcacccttac	cgagtcggcg	1860
acacagtgtg	ggtccgcccga	caccagacta	agaacctaga	acctcgctgg	aaaggacctt	1920
acacagtcct	gctgaccacc	cccaccgccc	tcaaagtaga	cggcatcgca	gcttggatac	1980
acgccgcccc	cgtgaaggct	gccgaccccc	gggggtggacc	atcctctaga	ctgccggatc	2040
ccagtgtggt	ggtaggggaat	tcaaaaaaaaa	aaatgtctca	gagcaaccgg	gagctgggtg	2100
ttgactttct	ctctacaag	ctttcccaga	aaggatacag	ctggagtcag	tttagtgatg	2160
tggaagagaa	caggactgag	gccccagaag	ggactgaatc	ggagatggag	acccccagtg	2220
ccatcaatgg	caaccatcc	tggcacctgg	cagacagccc	cgcgggtgaat	ggagccactg	2280
cgcacagcag	cagtttggat	gcccggggagg	tgatccccat	ggcagcagta	aagcaagcgc	2340
tgaggggaggc	aggcgacgag	tttgaactgc	ggtaccggcg	ggcattcagt	gacctgacat	2400
cccagctcca	catcacccca	gggacagcat	atcagagctt	tgaacaggta	gtgaatgaac	2460
tcttccggga	tggggtaaac	tggggtcgca	ttgtggcctt	tttctccttc	ggcggggcac	2520

11/18

aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4740
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4800
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4860
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4920
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4980
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5040
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5100
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaagaatt	5160
ggtcgaagct	tggcgagatt	ttcaggagct	aaggaagcta	aatggagaa	aaaaatcact	5220
ggatatacca	ccgttgatat	atcccaatgg	catcgtaaag	aacattttga	ggcatttcag	5280
tcagttgctc	aatgtaccta	taaccagacc	gttcagctgc	attaatgaat	cggccaacgc	5340
gcggggagag	gcggtttgcg	tattgggcgc	tcttcgctt	cctcgctcac	tgactcgctg	5400
cgctcggtcg	ttcggctgcg	gcgagcggta	tcagctcact	caaaggcgg	aatacggtta	5460
tccacagaat	caggggataa	cgcaggaaag	aacatgtgag	caaaaggcca	gcaaaaggcc	5520
aggaaccgta	aaaaggccgc	gttgctggcg	ttttccata	ggctccgccc	ccctgacgag	5580
catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	5640
caggcgtttc	cccctggaag	ctccctcgtg	cgctctcctg	ttccgaccct	gccgcttacc	5700
ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	tttctcaatg	ctcacgtgt	5760
aggtatctca	gttcggtgta	ggtcgttcgc	tccaagctgg	gctgtgtgca	cgaaccccc	5820
gttcagcccc	accgctgcgc	cttatccggt	aactatcgtc	ttgagtccaa	cccggtaaga	5880
cacgacttat	cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gaggatatgta	5940
ggcggtgcta	cagagttctt	gaagtggtag	cctaactacg	gctacactag	aaggacagta	6000
tttggtatct	gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	6060
tccggcaaac	aaaccaccgc	tggtagcggt	ggtttttttg	tttgcaagca	gcagattacg	6120
cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	ctacggggtc	tgacgctcag	6180
tggaacgaaa	actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	6240
tagatccttt	taaattaaaa	atgaagtttt	aatcaatct	aaagtatata	tgagtaaact	6300
tggtctgaca	gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctattt	6360
cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	ggagggctta	6420
ccatctggcc	ccagtgtctg	aatgataccg	cgagaccac	gctcaccggc	tccagattta	6480
tcagcaataa	accagccagc	cgggaaggcc	gagcgcagcc	gtggtcctgc	aactttatcc	6540
gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	taagtagttc	gccagttaat	6600
agtttgcgca	acgttggtgc	cattgctaca	ggcatcgtgg	tgtcacgctc	gtcgtttggt	6660
atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgttg	6720
tgcaaaaaag	cggttagctc	cttcggctct	ccgatcgttg	tcagaagtaa	gttgccgca	6780
gtgttatcac	tcatggttat	ggcagcactg	cataattctc	ttactgtcat	gccatccgta	6840

12/18

agatgctttt	ctgtgactgg	tgagtactca	accaagtcac	tctgagaata	gtgtatgcgg	6900
cgaccgagtt	gctcttgccc	ggcgtcaata	cgggataata	ccgcgccaca	tagcagaact	6960
ttaaaagtgc	tcattcattgg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttaccg	7020
ctgttgagat	ccagttcgat	gtaaccact	cgtgcaccca	actgatcttc	agcatctttt	7080
actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	aaaaaaggga	7140
ataaggcgca	cacggaaatg	ttgaatactc	atactcttcc	tttttcaata	ttattgaagc	7200
atttatcagg	gttattgtct	catgagcgga	tacatatattg	aatgtattta	gaaaaataaa	7260
caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	ctgacgtcta	agaaaccatt	7320
attatcatga	cattaaccta	taaaaatagg	cgtatcacga	ggccctttcg	tc	7372

<210> 4

<211> 953

<212> DNA

<213> homosapiens

<220>

<222> 1-953

<400> 4

gaattccggg	gggagagctg	gggcgagagg	tgccgttggc	cccgttgctt	ttcctctggg	60
aaggatggcg	cacgctggga	gaacggggta	cgacaaccgg	gagatagtga	tgaagtacat	120
ccattataag	ctgtcgcaga	ggggctacga	gtgggatgcg	ggagatgtgg	gcgccgcgcc	180
cccggggggc	gccccgcac	cgggcatctt	ctcctcccag	cccgggcaca	cgccccatcc	240
agccgcatcc	cgcgaccggg	tcgccaggac	ctcgccgctg	cagaccccg	ctgcccccg	300
cgccgccgcg	gggcctgcgc	tcagcccggt	gccacctgtg	gtccacctgg	ccctccgcc	360
agccggcgac	gacttctccc	gccgctaccg	cggcgacttc	gccgagatgt	ccagccagct	420
gcacctgacg	cccttcaccg	cgcggggacg	ctttgccacg	gtggtggagg	agctcttcag	480
ggacgggggtg	aactggggga	ggattgtggc	cttctttgag	ttcggtgggg	tcattgtgtg	540
ggagagcgtc	aaccgggaga	tgtcgcccct	ggtggacaac	atcgccctgt	ggatgactga	600
gtacctgaac	cggcacctgc	acacctggat	ccaggataac	ggaggctggg	atgcctttgt	660
ggaactgtac	ggccccagca	tgcggcctct	gtttgatttc	tcctggctgt	ctctgaagac	720
tctgctcagt	ttggccctgg	tgggagcttg	catcacctg	ggtgcctatc	tgagccacaa	780
gtgaagtcaa	catgcctgcc	ccaaacaaat	atgcaaaagg	ttactaaag	cagtagaaat	840
aatatgcatt	gtcagtgatg	taccatgaaa	caaagctgca	ggctgtttta	gaaaaataaa	900
cacgcacaac	atacacacat	acacatgcat	aaacatacac	acatacgga	ttc	953

13/18

<210> 5
 <211> 7996
 <212> DNA
 <213> homosapiens
 <220>
 <222> 2065-3016

<400> 5

ctcgaggagc	ttggcccatt	gcatacgttg	tatccatata	ataatatgta	catttatatt	60
ggctcatgtc	caacattacc	gccatgttga	cattgattat	tgactagtta	ttaatagtaa	120
tcaattacgg	ggtcattagt	tcatagccca	tatatggagt	tccgcgttac	ataacttacg	180
gtaaatggcc	cgcctggctg	accgcccac	gacccccgcc	cattgacgtc	aataatgacg	240
tatgttccca	tagtaacgcc	aatagggact	ttccattgac	gtcaatgggt	ggactattta	300
cggtaaactg	cccacttggc	agtacatcaa	gtgtatcata	tgccaagtac	gccccctatt	360
gacgtcaatg	acggtaaata	gcccgcctgg	cattatgccc	agtacatgac	cttatgggac	420
tttcctactt	ggcagtagat	ctacgtatta	gtcatcgcta	ttaccatgct	agagaacccat	480
cagatgtttc	caggggtgcc	caaggacctg	aaatgaccct	gtgccttatt	tgaactaacc	540
aatcagttcg	cttctcgttt	ctgttcgcgc	gcttctgtct	cccagagctca	ataaaaagagc	600
ccacaacccc	tactcggggg	cgccagtcct	ccgattgact	gagtcgcccc	ggtaccctgtg	660
tatccaataa	accctcttgc	agttgcatcc	gacttgtggg	ctcgtctgtt	cttgggaggg	720
tctcctctga	gtgattgact	accgctcagc	gggggtcttt	catttggggg	ctcgtccggg	780
atcgggagac	ccctgcccag	ggaccaccga	cccaccaccg	ggaggtaagc	tggccagcaa	840
cttatctgtg	tctgtccgat	tgtctagtgt	ctatgactga	ttttatgcgc	ctgcgtcggg	900
actagttagc	taactagctc	tgtatctggc	ggaccctgtg	tggaactgac	gagttcggaa	960
caccgcggcg	caaccctggg	agacgtccca	gggacttcgg	gggccgtttt	tgtggcccga	1020
cctgagtcca	aaaatcccga	tcgttttgga	ctctttgggt	caccccccta	ataggaggga	1080
tatgtgggtc	tggtaggaga	cgagaacctc	aaacagttcc	cgcctccgtc	tgaatttttg	1140
ctttcgggtt	gggaccgaag	ccgcgcgcgc	cgtcttgtct	gctgcagcat	cgttctgtgt	1200
tgtctctgtc	tgactgtgtt	tctgtatttg	tctgaaaatt	agggccagac	tgttaccact	1260
cccttaagtt	tgaccttagg	tactggaaa	gatgtcgagc	ggatcgctca	caaccagtcg	1320
gtagatgtca	agaagagacg	ttgggttacc	ttctgctctg	cagaatggcc	aacctttaac	1380
gtcggatggc	cgcgagacgg	cacctttaac	cgagacctca	tcaccaggt	taagatcaag	1440
gtcttttcac	ctggcccga	tggacacca	gaccaggtcc	cctacatcgt	gacctgggaa	1500
gccttggctt	ttgaccccc	tccctgggtc	aagccctttg	tacaccctaa	gcctccgcct	1560
cctcttcctc	catccgcccc	gtctctcccc	cttgaacctc	ctcgttcgac	ccgcctcga	1620
tcctcccttt	atccagccct	cactccttct	ctaggcgccc	atatgagatc	ttatatgggg	1680

14/18

cacccccgcc	ccttgtaa	ac	ttccctgacc	ctgacatgac	aagagttact	aacagcccct	1740
ctctccaagc	tcacttacag		gctctctact	tagtccagca	cgaagtctgg	agacctctgg	1800
cggcagccta	ccaagaacaa		ctggaccgac	cgggtggtacc	tcacccttac	cgagtcggcg	1860
acacagtgtg	gggccgccga		caccagacta	agaacctaga	acctcgctgg	aaaggacctt	1920
acacagtcct	gctgaccacc		cccaccgccc	tcaaagtaga	cggcatcgca	gcttggatac	1980
acgccgcccc	cgtgaaggct		gccgaccccc	gggggtggacc	atcctctaga	gtaatacgac	2040
tcactatagg	gcgtcgacgg		tatcgaattc	cggggggaga	gctggggcga	gaggtgccgt	2100
tggccccgtt	gcttttcctc		tgggaaggat	ggcgcacgct	gggagaacgg	ggtacgacaa	2160
ccgggagata	gtgatgaagt		acatccatta	taagctgtcg	cagaggggct	acgagtggga	2220
tgcgggagat	gtgggcgcgc		cgcccccggg	ggccgcccc	gcaccgggca	tcttctctc	2280
ccagccccgg	cacacgcccc		atccagccgc	atcccgcgac	ccggtcgcca	ggacctcgcc	2340
gctgcagacc	ccggtgcgcc		ccggcgccgc	cgcggggcct	gcgtcagcc	cggtgccacc	2400
tgtggtccac	ctggccctcc		gccaaagccg	cgacgacttc	tcccgcgct	accgcggcga	2460
cttcgccgag	atgtccagcc		agctgcacct	gacgcccttc	accgcgcggg	gacgctttgc	2520
cacggtgggtg	gaggagctct		tcagggacgg	ggtgaactgg	gggaggattg	tggccttctt	2580
tgagttcggt	ggggctcatgt		gtgtggagag	cgtcaaccgg	gagatgtcgc	ccctggtgga	2640
caacatcgcc	ctgtggatga		ctgagtacct	gaaccggcac	ctgcacacct	ggatccagga	2700
taacggaggc	tgggatgcct		ttgtggaact	gtacggcccc	agcatgcggc	ctctgtttga	2760
tttctcctgg	ctgtctctga		agactctgct	cagtttggcc	ctggtgggag	cttgcatac	2820
cctgggtgcc	tatctgagcc		acaagtgaag	tcaacatgcc	tgccccaaac	aaatatgcaa	2880
aaggttcact	aaagcagtag		aaataatatg	cattgtcagt	gatgtaccat	gaaacaaagc	2940
tgcaggctgt	ttaagaaaaa		ataacacgca	caacatacac	acatacacat	gcataaacat	3000
acacacatac	ggaattggcc		gcagtattct	atagtgtcac	ctaaatggat	cctctagaga	3060
attccccctc	tccctcccc		ccccctaacg	ttactggccg	aagccgcttg	gaataaggcc	3120
ggtgtgcgtt	tgtctatatg		ttattttcca	ccatattgcc	gtcttttggc	aatgtgaggg	3180
cccgaaacc	tggccctgtc		ttcttgacga	gcattcctag	gggtctttcc	cctctcgcca	3240
aaggaatgca	aggtctgttg		aatgtcgtga	aggaagcagt	tcctctggaa	gcttcttgaa	3300
gacaaacaac	gtctgtagcg		accctttgca	ggcagcggaa	ccccccacct	ggcgacaggt	3360
gcctctgcgg	ccaaaagcca		cgtgtataag	atacacctgc	aaaggcggca	caacccagct	3420
gccacgttgt	gagttggata		gttgtggaaa	gagtcaaatg	gctctcctca	agcgatttca	3480
acaaggggct	gaaggatgcc		cagaaggtac	cccattgtat	gggatctgat	ctggggcctc	3540
ggtgcacatg	ctttacatgt		gttttagtga	ggttaaaaaa	cgtctaggcc	ccccgaacca	3600
cggggacgtg	gttttccttt		gaaaaacacg	atgataagct	tgccacaacc	gacgcgtctc	3660
gaccattgtg	ctggaagatg		gattcatacc	tgctgatgtg	gggactgctc	acgttcatca	3720
tggtgccctg	ctgccaggca		gagctctgtg	acgatgacce	gccagagatc	ccacacgcca	3780
cattcaaagc	catggcctac		aaggaaggaa	ccatgttgaa	ctgtgaatgc	aagagaggtt	3840

15/18

tccgcagaat	aaaaagcggg	tcactctata	tgctctgtac	aggaaactct	agccactcgt	3900
cctgggacaa	ccaatgtcaa	tgacacaagct	ctgccactcg	gaacacaacg	aaacaagtga	3960
cacctcaacc	tgaagaacag	aaagaaagga	aaaccacaga	aatgcaaagt	ccaatgcagc	4020
cagtggacca	agcgagcctt	ccaggtcact	gcaggggaacc	tccaccatgg	gaaaatgaag	4080
ccacagagag	aattttatcat	ttcgtgggtg	ggcagatggt	ttattatcag	tgctgccagg	4140
gatacagggc	tctacacaga	ggtcctgctg	agagcgtctg	caaaatgacc	cacgggaaga	4200
caaggtggac	ccagccccag	ctcatatgca	caggtgaaat	ggagaccagt	cagtttccag	4260
gtgaagagaa	gcctcaggca	agccccgaag	gccgtcctga	gagtgaagact	tcctgcctcg	4320
tcacaacaac	agattttcaa	atacagacag	aaatggctgc	aaccatggag	acgtccatat	4380
ttacaacaga	gtaccaggta	gcagtggccg	gctgtgtttt	cctgctgac	agcgtcctcc	4440
tcctgagtgg	gctcacctgg	cagcggagac	agaggaagag	tagaagaaca	atctagccag	4500
cacaatggcg	gccgacgcgt	cccggagcca	tagataaaat	aaaagatttt	atttagtctc	4560
cagaaaaagg	ggggaatgaa	agaccccacc	tgtaggtttg	gcaagctagc	ttaagtaacg	4620
ccattttgca	aggcatggaa	aaatacataa	ctgagaatag	agaagttcag	atcaaggtea	4680
ggaacagatg	gaacagctga	atatgggcca	aacaggatat	ctgtggtaag	cagttcctgc	4740
cccggctcag	ggccaagaac	agatggaaca	gctgaatatg	ggccaaacag	gatatctgtg	4800
gtaagcagtt	cctgccccgg	ctcagggccca	agaacagatg	gtccccagat	gcggtccagc	4860
Cctcagcagt	ttctagagaa	ccatcagatg	tttccagggt	gccccaaagga	cctgaaatga	4920
ccctgtgcct	tatttgaact	aaccaatcag	ttcgtttctc	gcttctgttc	gcgcgtttct	4980
gctccccgag	ctcaataaaa	gagcccacaa	cccctcactc	ggggcgccag	tcctccgatt	5040
gactgagtcg	cccgggtacc	cgtgtatcca	ataaaccttc	ttgcagttgc	aaaaaaaaaa	5100
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5160
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5220
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5280
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5340
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5400
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5460
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5520
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5580
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5640
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5700
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	5760
aaaaaaaaaa	aaaaaaaaag	aattggtcga	agcttggcga	gattttcagg	agctaaggaa	5820
gctaaaatgg	agaaaaaat	cactggatat	accaccgttg	atatatccca	atggcatcgt	5880
aaagaacatt	ttgaggcatt	tcagtcagtt	gctcaatgta	cctataacca	gaccgttcag	5940
ctgcattaat	gaatcggcca	acgcgcgggg	agaggcgggt	tgctgtattg	gcgtctttcc	6000

16/18

gcttcctcgc	tactgactc	gctgcgctcg	gtcgttcggc	tgcggcgagc	ggtatcagct	6060
cactcaaagg	cggtaatacg	gttatccaca	gaatcagggg	ataacgcagg	aaagaacatg	6120
tgagcaaaag	gccagcaaaa	ggccaggaac	cgtaaaaagg	ccgcgttgct	ggcgtttttc	6180
cataggctcc	gccccctga	cgagcatcac	aaaaatcgac	gctcaagtca	gaggtggcga	6240
aacccgacag	gactataaag	ataccaggcg	tttccccctg	gaagctccct	cgtgcgctct	6300
cctgttccga	ccctgccgct	taccggatac	ctgtccgcct	ttctcccttc	gggaagcgtg	6360
gcgctttctc	aatgctcacg	ctgtaggtat	ctcagttcgg	tgtaggtcgt	tcgctccaag	6420
ctgggctgtg	tgcacgaacc	ccccgttcag	cccgaccgct	gcgccttata	cggtaactat	6480
cgtcttgagt	ccaacccggt	aagacacgac	ttatcgccac	tggcagcagc	cactggtaac	6540
aggattagca	gagcgaggta	tgtaggcggt	gctacagagt	tcttgaagtg	gtggcctaac	6600
tacggctaca	ctagaaggac	agtatttggg	atctgcgctc	tgctgaagcc	agttaccttc	6660
ggaaaaagag	ttggtagctc	ttgatccggc	aaacaaacca	ccgctggtag	cgggtggttt	6720
tttgtttgca	agcagcagat	tacgcgcaga	aaaaaaggat	ctcaagaaga	tcctttgatc	6780
ttttctacgg	ggtctgacgc	tcagtggaac	gaaaactcac	gttaagggat	tttggtcatg	6840
agattatcaa	aaaggatctt	cacctagatc	cttttaaatt	aaaaatgaag	ttttaaatca	6900
atctaaagta	tatatgagta	aacttgggtc	gacagttacc	aatgcttaat	cagtgaggca	6960
cctatctcag	cgatctgtct	atttcgttca	tccatagttg	cctgactccc	cgtcgtgtag	7020
ataactacga	tacgggaggg	cttaccatct	ggccccagtg	ctgcaatgat	accgcgagac	7080
ccacgctcac	cggctccaga	tttatcagca	ataaaccagc	cagccggaag	ggccgagcgc	7140
agccgtggtc	ctgcaacttt	atccgcctcc	atccagtcta	ttaattgttg	ccgggaagct	7200
agagtaagta	gttcgccagt	taatagtttg	cgcaacgttg	ttgccattgc	tacaggcatc	7260
gtgggtgcac	gctcgtcggt	tggtatggct	tcattcagct	ccggttccca	acgatcaagg	7320
cgagttacat	gatcccccat	gttgtgcaaa	aaagcgggta	gctccttcgg	tcctccgatc	7380
gttgtcagaa	gtaagttggc	cgcagtgtta	tactcatgg	ttatggcagc	actgcataat	7440
tctcttactg	tcatgccatc	cgtaagatgc	ttttctgtga	ctgggtgagta	ctcaaccaag	7500
tcattctgag	aatagtgtat	gcggcgaccg	agttgctctt	gcccggcgctc	aatacgggat	7560
aataccgcgc	cacatagcag	aactttaaaa	gtgctcatca	ttggaaaacg	ttcttcgggg	7620
cgaaaactct	caaggatctt	accgctgttg	agatccagtt	cgatgtaacc	cactcgtgca	7680
cccaactgat	cttcagcatc	ttttactttc	accagcgttt	ctgggtgagc	aaaaacagga	7740
aggcaaaatg	ccgcaaaaaa	gggaataagg	gcgacacgga	aatgttgaat	actcatactc	7800
ttcctttttc	aatattattg	aagcatttat	cagggttatt	gtctcatgag	cggatacata	7860
tttgaatgta	tttagaaaaa	taaacaaata	ggggttccgc	gcacatttcc	ccgaaaagtg	7920
Ccacctgacg	tetaagaaac	cattattatc	atgacattaa	cctataaaaa	taggcgtatc	7980
acgaggccct	ttcgtc					7996

17/18

<210> 6

<211> 38

<212> DNA

<220>

<222> 1-38

<400> 6

ccgaattctc gagcaccatg ctgggcatct ggaccctc

38

<210> 7

<211> 43

<212> DNA

<220>

<222> 1-43

<400> 7

ccgaattcta gaccaagctt tggatttcat ttctgaagtt tga

43

<210> 8

<211> 1890

<212> DNA

<213> homosapiens

<220>

<222> 1-1890

<400> 8

aaacagagag agatagagaa agagaaagac agaggtgttt cccttagcta tggaaactct	60
ataagagaga tccagcttgc ctctcttga gcagtcagca acagggtccc gtccttgaca	120
cctcagcctc tacaggactg agaagaagta aaaccgtttg ctggggctgg cctgactcac	180
cagctgccat gcagcagccc ttcaattacc catatcccca gatctactgg gtggacagca	240
gtgccagctc tccctgggcc cctccaggca cagttcttcc ctgtccaacc tctgtgcca	300
gaaggcctgg tcaaaggagg ccaccaccac caccgccacc gccaccacta ccacctccgc	360
cgcgcgccgc accactgcct ccactaccgc tgccaccctt gaagaagaga gggaaccaca	420
gcacaggcct gtgtctcctt gtgatgtttt tcatggttct ggttgccttg gtaggattgg	480
gcctggggat gtttcagctc ttccacctac agaaggagct ggccagaactc cgagagtcta	540
ccagccagat gcacacagca tcatcttttg agaagcaaat aggccacccc agtccacccc	600

18/18

ctgaaaaaaaa	ggagctgagg	aaagtggccc	atttaacagg	caagtccaac	tcaaggtcca	660
tgcctctgga	atgggaagac	acctatggaa	ttgtcctgct	ttctggagtg	aagtataaga	720
agggtggcct	tgtgatcaat	gaaactgggc	tgtactttgt	atattccaaa	gtatacttcc	780
ggggtcaatc	ttgcaacaac	ctgcccctga	gccacaaggt	ctacatgagg	aactctaagt	840
atccccagga	tctggtgatg	atggagggga	agatgatgag	ctactgcact	actgggcaga	900
tgtgggcccc	cagcagctac	ctgggggag	tgttcaatct	taccagtgtc	gatcatttat	960
atgtcaacgt	atctgagctc	tctctggtca	atcttgagga	atctcagacg	tttttcggct	1020
tatataagct	ctaagagaag	cactttggga	ttctttccat	tatgattctt	tgttacaggc	1080
accgagaatg	ttgtattcag	tgagggtctt	cttacaatgc	tttgaggtca	agtaagaaga	1140
catgaaccaa	gtggaccttg	agaccacagg	gttcaaaaat	tctgtagctc	ctcaactcac	1200
ctaattgttta	tgagccagac	aaatggagga	atatgacgga	agaacataga	actctgggct	1260
gccatgtgaa	gagggagaag	catgaaaaag	cagctaccca	ggtgtttctac	actcatctta	1320
gtgcctgaga	gtatttaggc	agattgaaaa	ggacaccttt	taactcacct	ctcaaggtgg	1380
gccttgctac	ctcaaggggg	actgtctttc	agatacatgg	ttgtgacctg	aggatttaag	1440
ggatggaaaa	ggaagactag	aggcttgcac	aataagctaa	agaggctgaa	agaggccaat	1500
gccccactgg	cagcatcttc	acttctaaat	gcatactctg	agccatcggt	gaaactaaca	1560
gataagcaag	agagatgttt	tggggactca	tttcattcct	aacacagcat	gtgtatttcc	1620
agtgcccaatt	gtaggggtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtatgact	aaagagagaa	1680
tgtagatatt	gtgaagtaca	tattaggaaa	atatgggttg	catttgggtca	agattttgaa	1740
tgcttcctga	caatcaactc	taatagtgtc	taaaaatcat	tgattgtcag	ctactaatga	1800
tgttttccta	taatataata	aatatttatg	tagatgtgca	tttttgtgaa	atgaaaacat	1860
gtaataaaaa	gtatatgtta	ggatacaaat				1890